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Abstract
Background: The INSIGHTS-IPF registry provides one of the largest data sets of clinical data and self-reported patient
related outcomes including health related quality of life (QoL) on patients with idiopathic pulmonary fibrosis (IPF). We
aimed to describe associations of various QoL instruments between each other and with patient characteristics at baseline.
Methods: Six hundred twenty-three IPF patients with available QoL data (St George’s Respiratory Questionnaire SGRQ,
UCSD Shortness-of-Breath Questionnaire SoB, EuroQol visual analogue scale and index EQ-5D, Well-being Index WHO-5)
were analysed. Mean age was 69.6 ± 8.7 years, 77% were males, mean disease duration 2.0 ± 3.3 years, FVC pred
was 67.5 ± 17.8%, DLCO pred 35.6 ± 17%.
Results: Mean points were SGRQ total 48.3, UCSD SoB 47.8, EQ-5D VAS 66.8, and WHO-5 13.9. These instruments had a
high or very high correlation (exception WHO-5 to EQ-5D VAS with moderate correlation). On bivariate analysis, QoL by
SGRQ total was statistically significantly associated with clinical symptoms (NYHA; p < 0.001), number of comorbidities
(p < 0.05), hospitalisation rate (p < 0.01) and disease severity (as measured by GAP score, CPI, FVC and 6-min walk test;
p < 0.05 each). Multivariate analyses showed a significant association between QoL (by SGRQ total) and IPF duration,
FVC, age, NYHA class and indication for long-term oxygen treatment.
Conclusions: Overall, IPF patients under real-life conditions have lower QoL compared to those in clinical studies. There
is a meaningful relationship between QoL and various patient characteristics.
Trial registration: The INSIGHTS-IPF registry is registered at Clinicaltrials.gov (NCT01695408).
Keywords: Patient related outcomes, Psychometrics, Idiopathic pulmonary fibrosis, Cohort study
Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing
interstitial lung disease associated with a high symptom
burden, significant comorbidities and early death [1–3].
Median survival is 3–5-years, shorter than for many
malignancies [4]. The antifibrotic drugs, pirfenidone
and nintedanib, slow lung function decline but have not
been convincingly shown to improve survival or quality of
life (QoL) [5, 6]. Beside prolonging survival, major aims
for IPF therapy include improving symptoms and QoL do-
mains like physical functioning, social participation and
emotional well-being [7].
A number of patient-reported outcome (PRO) measures
have been used in IPF research [8]. However, the majority
of PRO data were generated in single-center cohorts or
controlled clinical trials, and there are very limited
QoL response data from IPF patients collected under
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real-world conditions. Such data could be used to im-
prove understanding of disease burden at the individ-
ual and group levels, to better discern response to
therapeutic interventions and to plan for trials of novel
therapies.
In the present study, we aimed to summarize QoL data
collected in a nationwide, “real-world”, observational
registry of patients with IPF and to examine associations
between QoL and several other clinical variables.
Methods
INSIGHTS-IPF (“Investigating significant health trends in
idiopathic pulmonary fibrosis”) is an investigator-initiated,
multicenter (19 centers from all parts of Germany), obser-
vational registry study of data collected, within the con-
fines of routine clinical care, from patients with IPF since
November 2012. The study materials were approved by
the Ethics Committee of the Medical Faculty, Technical
University of Dresden, and by further local ethic commit-
tees as per local requirements. INSIGHTS-IPF is regis-
tered at Clinicaltrials.gov (NCT01695408). The protocol
[9, 10] and a detailed description of the baseline character-
istics of the cohort [1] have been previously published. In
brief, patients are eligible for enrolment if they are at least
18 years old, have IPF (definite, probable or possible, ap-
plying the 2011 IPF guideline [11]) based on physician
diagnosis, and have provided written informed consent.
There are no explicit exclusion criteria. Clinical data are
collected at enrolment and thereafter at 6-month inter-
vals. At follow-up visits, events such as hospitalization and
acute exacerbation (as judged by the treating physician)
are recorded. Data are reported via a secure internet based
data collection form.
Patient-reported outcome measures
Enrollees complete PROs at enrolment and yearly there-
after. PROs include the University of California San
Diego Shortness of Breath Questionnaire (UCSD SOB),
the St. George’s Respiratory Questionnaire (SGRQ), World
Health Organization-5 Well-Being Index (WHO-5) and
the EuroQol five-dimensional questionnaire (EQ-5D).
UCSD SOB
This questionnaire includes 24 items, each with a response
scale 0 (Not at all) to 5 (Maximally or Unable to do be-
cause of breathlessness). The total score ranges from 0 to
120, with a higher score indicating more severe dyspnea
[12, 13].
SGRQ
The SGRQ was originally developed for patients with
chronic obstructive pulmonary disease or asthma [14],
however, as a respiratory disease-specific instrument, it
has frequently been used in IPF [15]. There are 50 items
divided into three components (symptoms, activity, and
impacts). Scores for each component and a total score
range from 0 (highest QoL) to 100 (poorest QoL).
WHO-5
The 5 items of the questionnaire tap mood, vitality, and
general health. Each item is scored 0 to 5. The total
ranges from 0 to 25, with higher scores connoting better
well-being.
EQ-5D
The EQ-5D taps 5 domains (mobility, self-care, usual ac-
tivities, pain or discomfort, and anxiety or depression)
and is commonly used in cost-utility evaluation. Based
on domain scores, a sum utility score is calculated ran-
ging from negative values (−0.59 worse than death) to 1
(perfect state). Respondents also rate their current health
on a 20-cm vertical visual analogue scale (VAS) scored
from 0 to 100 [16].
Data collection and statistical analysis
Data were collected using an internet-based case report
form (eCRF) with automated plausibility checks. On-site
monitoring, with source data verification, was performed
in the majority of centers (currently 70%).
Summary statistics were generated for baseline data.
Pearson product-moment correlation coefficients and
univariate linear regression were used to examine associ-
ations between variables. Backward selection was used
to generate multivariable models using the following
candidate variable: disease duration, long-term oxygen
therapy, physician’s judgment on IPF behavior (stable,
slowly or rapidly progressing), NYHA stage, duration
since first symptoms in years, GAP index [17], number
and type of comorbidities (left heart insufficiency, coronary
heart disease (CHD), carotid stenosis, stroke, peripheral ar-
terial disease, atrial fibrillation, deep venous thrombosis
(DVT), pulmonary arterial embolism, pulmonary hyperten-
sion, arterial hypertension, reflux, diabetes mellitus, em-
physema, lung cancer, obstructive sleep apnea, depression/
depressive disorder, anxiety), 6-min walk distance, gender,
hospitalization in last 12 months, pulmonary rehabilitation,
and CPI. Standard errors and confidence intervals were es-
timated by the Huber White sandwich estimator to ac-
count for the clustering of patients within the study
centers. Data were analyzed with STATA 12.1 (StataCorp
LP. Stata Statistical Software: Release 12. College Station,
TX, USA).
Results
Baseline characteristics
Data for QoL were available for 623 of a total of 737 pa-
tients (84.5%). Baseline characteristics are presented in
Table 1. Patients mean age was 69.6 ± 8.7 years, 77.2%
Kreuter et al. Respiratory Research  (2017) 18:139 Page 2 of 10
were male; all but one were Caucasian (99.7%). Their
mean FVC was 67.5 ± 17.8% predicted and DLCO
35.6 ± 17% predicted. A comparison of baseline charac-
teristics of the 623 patients with and 114 patients with-
out available QoL data can be found in Additional file 1:
Table S1.
Patients were treated with antifibrotic therapies (49.5%),
oral glucocorticoids (23.7%); N-acetylcysteine (33.7%), and
long-term O2 therapy (32.3%). Most (90.0%) had definite
IPF, 5% probable IPF, and 5% possible IPF. At enrolment,
treating physicians rated IPF as stable in 36.3%, slowly
progressing in 30.9% and rapidly progressing in 11.2%.
PRO scores and their inter-correlations at enrolment
Baseline values for PROs and their inter-correlations are
shown in Table 2. According to the SGRQ, the greatest
impairment was in the activity component. Based on the
WHO-5 index, 46.4% of the patients showed depressive
symptoms.
Associations between PRO scores and clinical variables at
enrolment
For the SGRQ, associations with various demographic
and clinical characteristics of patients at baseline are
shown in Fig. 1. Statistically significantly higher total
SGRQ score (indicating reduced QoL) were associated
with lower age (51.8 for patients ≤60 years versus 46.9
for patients >65 years), female gender (46.9 for male ver-
sus 53 for female), higher NYHA classes (compared to
NYHA class I), longer duration of symptoms, higher
CPI, lower %FVC, and higher GAP stage (Fig. 1). Correla-
tions between QoL and %DLCO (EQ-5D: 0.28, p < 0.001;
SGRQ: -0.26, p < 0.001; UCSD: -0.22, p < 0.001) or %FVC
(EQ-5D: 0.33, p < 0.001; SGRQ: -0.40, p < 0.001; UCSD:
-0.43, p < 0.001) were moderately strong. Patients without
comorbidity had a mean SGRQ total score of 44; those
with 2 comorbidities 47; and those with ≥4 comorbidities
59 (ANOVA, p < 0.001 for difference between groups)
(Table 3). QoL was also significantly associated with some
types of pharmacological and non-pharmacological ther-
apies of patients with IPF (Table 4).
In multivariate models (Table 5), LTOT, GAP index
(stage III), physician’s judgement (rapid progression),
and NYHA class were independent predictors of EQ-5D
VAS. The same variables (except for the GAP index)
were associated with SGRQ total score.
Both the EQ-5D index and the EQ-5D TTO were sta-
tistically significantly associated with LOT, the 6-MWD
and the NYHA functional class (II, III, and IV). The
WHO-5 was associated with LOT, and NYHA class III
and IV. Finally, the UCSD SoB was associated with LOT,
and NYHA class and %FVC.
Discussion
Idiopathic pulmonary fibrosis (IPF) is not only a severe
life-shortening disease; it also significantly impairs pa-
tients’ quality of life. In this study, we present data from a
large cohort of IPF patients. To our knowledge, this is one
of the first-presentations of such data collected under
real-world conditions. Overall, impairment in QoL and
symptom burden were immense.
Compared to a very recent report from the Australian
IPF registry, QoL impairment was very similar with a
SGRQ total score of 46.6 (and 48.3 in our registry). Simi-
larly, to the data presented here, an association between
QoL and dyspnoea and physiological data were reported.
Yet, in contrast to our analyses also cough and depres-
sion were major contributors to diminished QoL –
reasons for this may be explained by different tools
used to assess depression (HADS) and a structured
Table 1 Baseline characteristics
Characteristic Value
Male sex 481 (77.2%)
Age, years 69.6 ± 8.7
Body mass index, kg/m2 27.5 ± 4.1
Underweight 4 (0.6%)
Normal weight 167 (26.8%)
Overweight 305 (49.0%)
Obesity 147 (23.6%)
Age at first symptom onset, years 65.8 ± 10.1
Age at IPF diagnosis, years 67.6 ± 9.6
Duration since first symptoms, years 3.6 ± 4.0
Disease duration, years 2.0 ± 3.3
Disease duration of less than 6 months 242 (38.8%)
Smoking status
Never 237 (38.0%)
Former 376 (60.4%)
Current 10 (1.6%)
Gastro-oesophageal reflux 192 (30.8%)
Emphysema 55 (8.8%)
Genetic predisposition 31 (5.0%)
Six-minute walk distance, meters 272.4 ± 196.1
% FVC 67.5 (±17.8)
% FEV1 75.3 (±19.4)
% DLCO 35.6 (±17.0)
Long term oxygen use 201 (32.3%)
GAP index
Stage I 87 (20.2%)
Stage II 238 (55.2%)
Stage III 106 (24.6%)
Based on sample of patients with HrQoL data (n = 623). Values are n (%) or
mean ± standard deviation
GAP Gender, Age, Physiology index
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Table 2 Correlations between different measures of QoL at baseline
Green fields highlight very strong (r ≥ 0.80) or strong (r ≥ 0.60–0.79) correlations, yellow fields moderate (r = 0.30–0.59) correlation
Fig. 1 QoL Scores by Disease severity (* p < 0.05 in reference to the first category)
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tool to assess cough severity [18]. Another, yet retro-
spective very recently published cohort of 182 IPF pa-
tients reported an association between the SGRQ total
score and overall survival [19]. In comparison to
recently-completed, randomised controlled drug trials,
the patients in our registry had more severe QoL im-
pairment and a higher symptom burden. For example,
in the two INPULSIS trials of nintedanib, which to-
gether included 1066 patients, the mean total SGRQ
score was 39.4–39.8 points in the various arms [20]; it
was 48.3 in our registry. The same is true of other
drug trials for IPF: ambrisentan (492 subjects: mean
SGRQ total 40.5–44.5) [21], interferon gamma-1b (826
subjects: 41.6–42.4) [22]. Similarly, mean UCSD dyspnea
score was higher in this registry (47.8) than participants in
recently conducted trials (e.g., the ASCEND trial on pirfe-
nidone, 555 patients, mean UCSD 34.0–36.6 points). [23]
Such differences in symptoms and QoL are likely ex-
plained by differences in disease severity and baseline
characteristics. For example, in our real world cohort, the
burden of comorbidities known to portend a worse prog-
nosis in IPF [3] was not insignificant, with 322 (51.7%) of
our registry enrollees having at least two comorbid condi-
tions [1]. These patients would have been excluded from
most drug trials.
To our knowledge, this is the first time, investigators
have assessed the association between the presence of
specific comorbid conditions and QoL. We observed that
comorbid conditions contribute greatly to QoL impair-
ment. However, additional research is needed to deter-
mine if therapeutic targeting comorbidities will improve
QoL in these patients. Although other investigators have
assessed QoL in IPF patients under real-world conditions,
they found no correlation between various baseline char-
acteristics and QoL [24]. This may stem from a lack of
power. In our cohort, SGRQ total score was higher in
women than men, an observation noted by other investi-
gators [25]. The reason for this difference is unknown but
merits further investigation.
Like other investigators, we found that QoL was more
impaired in patients on LTOT than in those not on
LTOT. In fact, LTOT was an independent predictor of
QoL even with adjustment for disease severity [24, 26].
This likely stems from the real and perceived con-
straints LTOT places on patients [27]. QoL impairment
was also greater among patients who were prescribed
anti-inflammatory therapy, anti-reflux therapy and other
non-pharmacological interventions. In this observational
study, causation cannot be discerned, and more research
is needed to improve understanding of these results.
In several studies, investigators reported correlation coef-
ficients between the SGRQ and one or more other patient-
related assessment of health related quality of life, health
status or symptoms including the Borg Dyspnea Index
Table 5 Predictors of QoL in stepwise multivariable linear regression analyses
EQ-5D VAS WHO-5 SGRQ UCSD
Beta 95% CI p value Beta 95% CI p value Beta 95% CI p value Beta 95% CI p value
Age 0.28 0.05; 0.52 0.018
Disease duration in months 0.07 0.02; 0.12 0.010
GAP index
Stage I (ref)
Stage II −5.02 −10.78; 0.74 0.087
Stage III −12.24 −19.71; −4.78 0.001
Physician’s overall judgment
Stable disease (ref) (ref) (ref)
Slow progression −5.46 −12.48; 1.55 0.126 −0.42 −1.61; 0.76 0.484 2.59 −3.36; 8.54 0.392
Rapid progression −15.28 −25.42; −5.14 0.003 −2.74 −4.73; −0.75 0.007 9.06 1.35; 16.76 0.021
No judgement possible −5.43 −12.72; 1.86 0.144 −0.43 −1.68; 0.81 0.495 2.40 −3.98; 8.77 0.460
Long-term oxygen therapy −14.31 −20.66; −7.95 <0.001 −3.20 −4.32; −2.08 <0.001 7.42 1.74; 13.10 0.011 22.99 13.50; 32.48 <0.001
NYHA functional class
I (ref) (ref) (ref)
II −8.52 −15.67; −1.37 0.020 12.85 5.76; 19.94 <0.001 15.78 7.55; 24.01 <0.001
III −7.40 −15.36; 0.55 0.068 21.05 13.06; 29.04 <0.001 28.96 18.96; 38.95 <0.001
IV −24.87 −37.41; −12.32 <0.001 29.63 19.32; 39.94 <0.001 38.49 22.48; 54.51 <0.001
FVC %pred 0.04 0.01; 0.07 0.006 −0.21 −0.36; −0.06 0.005 −0.33 −0.57; −0.09 <0.001
Considered variables in stepwise multivariable linear regression analyses: Disease duration, FVC %pred, Long-term oxygen therapy, Age, Physician’s overall judg-
ment, NYHA stage, Duration since first symptoms, GAP index, No. of comorbidities, 6MWD, Sex, Hospitalisation in last 12 months, Pulmonary rehabilitation, CPI
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[26, 28], Cough Quality of Life Questionnaire [29], the
Baseline Dyspnea Index [28, 30, 31], King’s Brief Intersti-
tial Lung Disease questionnaire, [32, 33] Dyspnea Score
[34], Short-Form 36 Physical Component Summary [28],
Dyspnea-12 [35], and UCSD SoB questionnaire [7] among
others. Overall, there were moderate to strong correlation
between the SGRQ total score and the total score of these
instruments [15], thus supporting the validity of the
SGRQ total to capture QoL in patients with IPF. It is re-
assuring that data from our study mirror results from
these other studies. Like them, our results support the
validity of the SGRQ (and the other instruments used
in INSIGHTS) for use in IPF, including a large, real-world,
German cohort. In future research, shorter questionnaires
with longitudinal and cross-cultural validity should be de-
veloped for use in daily patient care [32, 33].
In IPF patients, a major challenge is how to improve
QoL impairment. Currently, only sildenafil, pulmonary
rehabilitation or specialized, multi-modality treatment
programs may have a role [36–38]. Unfortunately, the
two globally-approved anti-fibrotic drugs, nintedanib and
pirfenidone, have not been shown to do so. Hopefully,
ongoing development and research efforts will lead to
therapeutic interventions that allow IPF patients to live
better with the disease.
There are limitations to our study. The QoL assessment
tools we used were not originally developed for IPF, but
they do have data to support their validity in this disease.
Instruments such as the K-BILD [32] or A Tool to As-
sess Quality of Life in Idiopathic Pulmonary Fibrosis
(ATAQ-IPF-cA) [39] which were developed for patients
with interstitial lung disease may have reflected impair-
ments more precisely in our cohort. However, these instru-
ments’ psychometric properties have yet to be examined in
German patients. Because all registry patients were being
treated in specialized ILD centers, these results may not
generalize to the larger IPF population. IPF was diagnosed
at the participating centers according to current guidelines
without undergoing another central MDT review which
may explain some differences between the results reported
here and clinical trial cohorts, although recent data suggest
that experienced physicians are very accurate in diagnosing
IPF [40]. Further, QoL data may have been biased in the
cohort reported here as incident IPF patients were slightly
underrepresented compared to patients without available
HrQoL data. However, a strength of the INSIGHTS-IPF
registry is that enrollees were prospectively and consecu-
tively recruited, and it employs source data verification,
statistical plausibility checks and queries.
Conclusions
Health related quality of life is substantially impaired in
patients with IPF, and drivers of this impairment include
symptoms, comorbidities, LOT and disease severity.
While current treatments improve the course of the dis-
ease and perhaps survival, additional investigation is
needed to identify interventions that durably to improve
this important outcome in IPF patients.
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